MC2 Interactive

MC2 Therapeutics is a commercial-stage pharmaceutical company focused on developing novel treatment paradigms in dermatology and other chronic inflammatory conditions. The company utilizes its proprietary PAD Technology, a formulation platform that enables the creation of stable, high-concentration topical products with improved patient experience and efficacy. Its lead product, Wynzora Cream, is FDA and EMA approved for the treatment of plaque psoriasis and is marketed globally through strategic partnerships. MC2 Therapeutics is also advancing a clinical pipeline of candidates targeting conditions such as lichen sclerosus, chronic kidney disease-associated pruritus, and dry eye disease.